{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:18Z","timestamp":1792839738852,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jhep.2020.11.040","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T19:50:41Z","timestamp":1606852241000},"page":"952-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Residual risk of liver disease after hepatitis C virus eradication"],"prefix":"10.1016","volume":"74","author":[{"given":"Francesco","family":"Negro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jhep.2020.11.040_bib1","first-page":"30548-1","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"S0168-8278","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib3","doi-asserted-by":"crossref","first-page":"524-531","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib5","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib6","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA Therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET Cohort","author":"Verna","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/hepr.13418","article-title":"Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy","volume":"49","author":"Ogasawara","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.040_bib10","doi-asserted-by":"crossref","first-page":"130-137","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.jhep.2020.11.040_bib11","first-page":"32273-0","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"S0168- 8278","author":"Ioannou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.11.040_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.040_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk","author":"Janjua","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2020.11.040_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2020.11.040_bib21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2020.11.040_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"Van der Meer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0040-1702944","article-title":"Postsustained virological response management in hepatitis C patients","volume":"40","author":"Masetti","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2020.11.040_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2020.11.040_bib25","first-page":"S0168","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: an ERCHIVES study [published online ahead of print, 2020 Mar 5]","author":"Butt","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib26","doi-asserted-by":"crossref","first-page":"e0171755","DOI":"10.1371\/journal.pone.0171755","article-title":"Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response","volume":"12","author":"Welsch","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.11.040_bib27","first-page":"139","article-title":"Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C","volume":"57","author":"Mauss","year":"2019","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.040_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/liv.14186","article-title":"Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs","volume":"40","author":"Tacke","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.26644","article-title":"Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection","volume":"59","author":"Wiese","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib30","article-title":"Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C","author":"Benhammou","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.11.040_bib31","first-page":"848","article-title":"Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up","volume":"55","author":"Schlevogt","year":"2017","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.040_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5152\/tjg.2019.18514","article-title":"A\u00a0significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens","volume":"30","author":"Kassas","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.040_bib33","article-title":"Excess weight gain after cure of hepatitis C infection with direct-acting antivirals","author":"Do","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jhep.2020.11.040_bib34","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/MEG.0b013e3283589f63","article-title":"Taste and appetite disorders of chronic hepatitis C patients","volume":"24","author":"Musialik","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.11.040_bib37","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0168-8278(12)60007-5","article-title":"The interaction of metabolic factors with HCV infection: does it matter?","volume":"56","author":"Bugianesi","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"24","author":"Noureddin","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.040_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12072-012-9388-x","article-title":"Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy","volume":"7","author":"Chen","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/jvh.13167","article-title":"Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response","volume":"26","author":"Peleg","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","article-title":"Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4","volume":"41","author":"Dawood","year":"2017","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jhep.2020.11.040_bib42","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib43","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","article-title":"Pegylated interferon\u2013induced immune-mediated hepatitis post\u2013liver transplantation","volume":"12","author":"Kontorinis","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2020.11.040_bib47","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.transproceed.2011.05.028","article-title":"Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports","volume":"43","author":"Casanovas","year":"2011","journal-title":"Transpl Proc"},{"key":"10.1016\/j.jhep.2020.11.040_bib48","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/0016-5085(92)90786-X","article-title":"Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C","volume":"102","author":"Shindo","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib49","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/0016-5085(95)90139-6","article-title":"Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C","volume":"108","author":"Garcia-Buey","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/TP.0000000000001708","article-title":"International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2020.11.040_bib52","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib53","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","article-title":"Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study","volume":"13","author":"Ide","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib55","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study","author":"Shiha","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","article-title":"Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin-free treatment","volume":"38","author":"Kozbial","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000470910","article-title":"Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease","volume":"93","author":"Ogata","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2020.11.040_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/jir.2019.0049","article-title":"Aspartate aminotransferase-to-platelet ratio or FIB-4 index predicts the development of hepatocellular carcinoma in chronic hepatitis C patients with sustained virologic response to interferon therapy","volume":"39","author":"Na","year":"2019","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.jhep.2020.11.040_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30733-9","article-title":"Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease","author":"Semmler","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib62","doi-asserted-by":"crossref","first-page":"67-74","DOI":"10.1016\/j.jhep.2014.02.022","article-title":"Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication","volume":"61","author":"Huang","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000470910","article-title":"Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease","volume":"93","author":"Ogata","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2020.11.040_bib64","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.2061","article-title":"Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study","volume":"8","author":"Nakano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2020.11.040_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk","author":"Janjua","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib66","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/hepr.13278","article-title":"Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection","volume":"49","author":"Watanabe","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.040_bib69","first-page":"378","article-title":"Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C","volume":"32","author":"Chun","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib70","series-title":"Predictive models for hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C and sustained virological response (SVR) achieved with direct-acting antiviral (DAA) included in the ANRS CO22 hepather cohort","author":"Ganne-Carri\u00e9","year":"2020"},{"key":"10.1016\/j.jhep.2020.11.040_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/apt.15976","article-title":"Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination","volume":"52","author":"Ogawa","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.11.040_bib72","series-title":"The dynamics of FIB4 after sustained viral response predicts the risk of liver-related complication in HCV cirrhosis (ANRS CO12 CirVir)","author":"Boursier","year":"2020"},{"issue":"20","key":"10.1016\/j.jhep.2020.11.040_bib73","first-page":"30394-9","article-title":"Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status","volume":"S0168-8278","author":"Audureau","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31588","article-title":"A\u00a0model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis","author":"Alonso L\u00f3pez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/liv.14226","article-title":"Intrahepatic immune changes after hepatitis C virus eradication by direct-acting antiviral therapy","volume":"40","author":"Amaddeo","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000490360","article-title":"HCC immune surveillance and antiviral therapy of hepatitis C virus infection","volume":"8","author":"Owusu Sekyere","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2020.11.040_bib77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.15403\/jgld-309","article-title":"Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronic hepatitis C","volume":"28","author":"Simili","year":"2019","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhep.2020.11.040_bib78","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/hepr.13307","article-title":"Association of serum interferon-\u03bb3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents","volume":"49","author":"Inoue-Shinomiya","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.040_bib79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jgh.14359","article-title":"Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication","volume":"34","author":"Huang","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.040_bib80","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2017.01.041","article-title":"Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection","volume":"15","author":"Matsuura","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00535-018-1526-3","article-title":"TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy","volume":"54","author":"Iio","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.040_bib82","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/j.gastro.2017.04.056","article-title":"TLL1 rs17047200 increases the risk of fibrosis progression in Caucasian patients with chronic hepatitis C","volume":"153","author":"John","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib83","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jvh.13155","article-title":"TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals","volume":"26","author":"Degasperi","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.11.040_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31500","article-title":"Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs","author":"Degasperi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.040_bib85","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.11.040_bib86","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3892\/ol.2017.5732","article-title":"Sphingosine kinase 1: a novel independent prognosis biomarker in hepatocellular carcinoma","volume":"13","author":"Cai","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jhep.2020.11.040_bib87","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1111\/liv.14178","article-title":"Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response","volume":"39","author":"M\u00fccke","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.040_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008181","article-title":"Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals","volume":"15","author":"Perez","year":"2019","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhep.2020.11.040_bib89","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:14Z","timestamp":1759174934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820338277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0168827820338277"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.040","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual risk of liver disease after hepatitis C virus eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}